Research team behind the phase 2b trial
Appears in 1 story
Reported inconclusive primary results in JAMA Psychiatry
The largest European trial of psilocybin for treatment-resistant depression failed its primary test. In results published this week in JAMA Psychiatry, 17% of patients who received one guided 25-milligram dose met the response threshold at six weeks, versus 10.6% on an active placebo. The gap missed statistical significance.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
